Evidence & policy library

Every pathway is linked to the organizations responsible for the decision.

Market

8 source records

Methodology

Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.

Content & use

Matching documents: 8

Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked

APAC

🇰🇷 South KoreaKR-S01 · MFDS · Approval Process — DrugsOfficiallegal approval, dossier, workflowcurrent frameworkLatest observed: checked live2026-08-01 🇰🇷 South KoreaKR-S02 · NHIS · 약가협상 업무(절차) 소개Officialpositive list and negotiation purposepositive list from 2006-12-29Latest observed: checked live2026-08-01 🇰🇷 South KoreaKR-S03 · NHIS · 약가협상 대상 의약품 / 사용량-약가 연동Officialsequence, omission, expansion, volume triggerscurrent operational pageLatest observed: checked live2026-08-01 🇰🇷 South KoreaKR-S04 · HIRA · 2025 HIRA functions and roles — pharmaceutical reimbursementOfficialDREC role and evaluation scope2025Latest observed: published 20252026-08-01 🇰🇷 South KoreaKR-S05 · HIRA · 경제성평가 제출 약제 비용효과성 평가결과 공개OfficialICER interpretation and non-fixed threshold2022Latest observed: 20222026-08-01 🇰🇷 South KoreaKR-S06 · MOHW · 소아백혈병치료제 등 중증질환 치료약제 건강보험 적용 확대OfficialRSA purpose, scope, refund, volume policyeffective 2013-12-31Latest observed: 2013-12-302026-08-01 🇰🇷 South KoreaKR-S07 · MOHW · 건정심, 국민건강보험 약가 조정 및 제도개선 의결Officialflexible contract, reassessment, generics, lifecycle reformdecision 2026-03-26Latest observed: checked live2026-08-01 🇰🇷 South KoreaKR-S08 · MFDS · 2025 Drug Approval ReportOfficialcurrent approval context; not used for pathway rulesreport 2025Latest observed: 2026-07-032026-08-01

For education only — not regulatory, pricing or legal advice.